A director at Illumina Inc bought 7,330 shares at 135.290USD and the significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Moody's Investors Service ("Moody's") has revised the outlook of Illumina, Inc. ("Illumina") to negative from stable. Concurrently, Moody's affirmed Illumina's Baa3 issuer and senior unsecured ratings. The revision of the outlook to negative reflects Moody's expectation that Illumina will operate ...
Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of $1 billion of senior unsecured notes of Illumina, Inc ("Illumina"). There are no changes to Illumina's existing Baa3 issuer rating or the stable outlook. Proceeds of the offering will be used to repay upcomin...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Moody's Investors Service commented that the adverse verdict in a patent infringement lawsuit is credit negative but manageable for Illumina, Inc. Despite its large amount ($334 million), Illumina is in a position to absorb this large adverse monetary award thanks to $1.35 billion of cash on hand an...
The independent financial analyst theScreener just awarded an improved star rating to ILLUMINA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 18, 2022, the closi...
Hillenbrand (HI) has pivoted successfully to roll-up the industrial machinery industry in the past decade, giving the business greater growth potential and opportunities for asset efficiency. Uniform Accounting highlights these efficiency improvements that the market is missing, indicating equity upside. Over the last decade, Hillenbrand has expanded its business from a casket business into the industrial machinery industry, causing Uniform ROA to improve to stable 25%-28% levels. It has acqu...
Illumina, Inc. (ILMN:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) earnings, with a 44.0x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm, but management may be concerned about the sustainability of margin improvements, shipment levels, and the potential of their Popseq pipeline. Specifically, management may lack confidence in their ability to sustain NextSeqDx record shipments, high NovaSeq order volume, and non-GAAP o...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: UBS Genomics 2.0 and MedTech Innovations Summit on August 11, 2021 Fireside Chat at 12:00 pm Pacific Time (3:00 pm Eastern Time) The live webcast can be accessed under the Investor Info section of the "company" tab at . A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovat...
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection. “This acquisition is procompetitive, and we have offered far-reaching structural and behavioral remedies to address any potential concerns. Illumina will continue to work with the European Commission (EC) to ensure that it has the information and assurances necessary to approve this transaction. We look forward to presenting our position during the Phase II process,” said Charles Dadswell, General Counsel for Illumina. Ill...
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the second quarter 2021 following the close of market on Thursday, August 5, 2021. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, August ...
SAN DIEGO--(BUSINESS WIRE)-- Today, Illumina, Inc. (NASDAQ:ILMN) announced an agreement with the Belgian Genetic Centers to evaluate whole-genome sequencing (WGS) for the diagnosis of patients with intellectual disabilities (ID) and/or developmental disorders (DD) in routine care. The study, run by the Belgian Resolve Rare Diseases group (BeSolveRD), will also assess the health economic impact of WGS versus current standards of care. BeSolveRD will recruit 800 pediatric patients (neonates, children or adolescents) with ID/DD, plus their parents, from all eight Belgian Genetic Centers. Half of...
MELBOURNE, Australia--(BUSINESS WIRE)-- Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, today announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal testing (NIPT). This press release features multimedia. View the full release here: Illumina's VeriSeq NIPT Solution v2 (Photo: Business Wire) The automated in-lab IV...
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021 Fireside Chat at 7:30 am Pacific Time / 10:30 am Eastern Time The live webcast can be accessed under the Investor Info section of the "company" tab at . A replay will be posted on Illumina’s website after the event and will be available for at least 30 days following. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.